Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

International Clinical Psychopharmacology

Volumn 23, Issue 5, 2008, Pages 243-253

  Boyer, Patrice ^a   Montgomery, Stuart ^b   Lepola, Ulla ^c   Germain, Jean Michel ^d   Brisard, Claudine ^d   Ganguly, Rita ^e   Padmanabhan, Sudharshan K ^e   Tourian, Karen A ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Kuopion Psykiatripalvelu Oy   (Finland)

^d Clinical Research and Development   (France)

^e PFIZER INC   (United States)

Author keywords

Antidepressant; Desvenlafaxine; Major depressive disorder

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; DESVENLAFAXINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VERTIGO; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 54449099975     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32830cebed     Document Type: Article

References (31)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:21-27.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
3. Cook RJ, Sackett DL (1995). The number needed to treat: a clinically useful measure of treatment effect. Erratum in: BMJ 1995; 310(6986):1056. Br Med J 310:452-454.
4. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, et al. (2006). Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665.
5. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL (1998). The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 86:102-106.
6. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68:677-688.
7. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24:389-399.
8. Guy W, editor (1976). Clinical global impressions. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication ADM 76-338. pp. 217-222.
9. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
11. Khan A, Warner HA, Brown WA (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57: 311-317.
12. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W (2004). Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161:2045-2049.
13. Kraemer HC, Kupfer DJ (2006). Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990-996.
14. Liebowitz M, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 24:1877-1890.
15. Lipman RS (1982). Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18:69-77.
16. Montgomery SA (1994). Clinical relevant effect sizes in depression.Eur Neuropsychopharmacol 4:283-284.
17. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
18. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370:851-858.
19. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
20. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.
21. Papakostas GI, Fava M, Thase ME (2008). Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63:699-704.
22. Pristiq [package insert] (2008). Philadelphia, PA; Wyeth Pharmaceuticals.
23. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77-87.
24. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998). A randomized, placebo-controlled, dose-response trial of venlafaxine hydro-chloride in the treatment of major depression. J Clin Psychiatry 59:116-122.
25. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22:338-347.
26. Sheehan DV (2000). Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, Blacker D, Endicott J, Keith SJ, et al., editors. Handbook of Psychiatric Measures, 1st ed. Washington, DC: American Psychiatric Association. pp. 113-115.
27. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33.
28. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180:396-404.
29. Thase ME (2002). Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? J Clin Psychiatry 63 (Suppl 2):24-28.
30. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
31. World Health Organization (1998). Wellbeing measures in primary health care/ the depcare project. Copenhagen, Denmark: WHO Regional Office for Europe.